Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy by Ionis to treat polycythemia ...

We have therefore made the assessment that COVID-19 can be characterized as a pandemic,” he says. During the first European ...

In December 2020 a new mRNA jab from Pfizer BioNTech ... of countries suspended the vaccine's use after unusual but rare blood clots were detected in a small number of immunized people.

Researchers racing to develop bird flu vaccines for humans have turned to a cutting-edge technology that enabled the rapid development of lifesaving covid shots.

Attorneys general from 17 states are preparing to take legal action against Dr. Anthony Fauci for his conduct during the ...

CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot is in phase 1 testing.

A single molecular switch is essential for blood stem cells to enter an activated, regenerative state in which they produce new blood cells, according to a preclinical study led by Weill Cornell ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

"Journalist" Paul Thacker defends Dr. Jay Bhattacharya and the Great Barrington Declaration by rehashing the same old ...

In February 2025, Stryker acquired Inari Medical Inc. (NASDAQ: NARI), which gives Stryker a foothold in the fast-growing field of venous thromboembolism (VTE) clot removal. Stryker’s ...

Blood clots are a leading cause of ischemic strokes, as they block blood flow to the brain. Previous studies suggest that people with blood type A may be more prone to developing clots in the legs ...

The results offer hope for future fracture ... Jan. 22, 2025 — Following the lead of previous work on mRNA-based vaccines, therapies for spinal cord injuries and more, the method relies upon ...